Prof Federica Cavallo, PhD, MSc

Immunology — University of Turin, Italy

LeadR Profile

Prof Federica Cavallo, PhD, MSc University of Turin Italy
1 873 ScienceLeadR Reputation 1873
Network Map

Immunology

Subspecialties: Hematology - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026

Source: PubMed

University of Turin

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 517

Citations

Citations: 18 002 1st author: 30 Last author: 77 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable.
cells, neoplasms, immunotherapy, immunity, therapeutics, tumor microenvironment, osteosarcoma
Cancers (Basel)20260
STING-mediated tumor microenvironment remodeling: turning adaptive resistance into therapeutic vulnerability.
cells, antibodies, neoplasms, immune system diseases, immunity, therapeutics, tumor microenvironment
Front Immunol20260
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
cells, genes, lymphoma, biomarkers, lymph, lymphoma, mantle-cell, mutation
Blood Adv20260
Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.
cells, hematology, lymphoma, b-cell, lymphoma, therapeutics, b-lymphocytes, prognosis, salvage therapy, car-t cell
Haematologica20260
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.
lymphoma, follicular, transplantation, autologous, lymphoma, transplantation
Hemasphere20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 13
Phase 3 13
Phase 2 7
Phase 1 1
Phase 1/Phase 2 1

By status:

Recruiting 13
Completed 10
Active not recruiting 8
Unknown 3
Terminated 1

By type:

Interventional 25
Observational 10

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 29

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An unblinded multi center study evaluating long term treatment with Zanubrutinib (BGB 3111) regimens in patients with blood cancer in the lymph node
2024-511267-28-00 — cells, blood, lymph nodes, neoplasms, multiple chronic conditions, lymph, therapeutics, b-lymphocytes
Phase 3Active not recruiting2021
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab versus Lenalidomide plus Rituximab in patients With Relapsed Refractory (R R) Follicular Lymphoma Grade 1 to 3a or R R Marginal Zone Lymphoma
2023-504684-16-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics
Phase 3Active not recruiting2021
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well Tolerated and How Well it Works Compared to Rituximab Combined with Chemotherapy for Adult Participants with Follicular Lymphoma
2022-502113-28-00 — lymphoma, follicular, safety, lymphoma, drug therapy, rituximab, chemotherapy
Phase 3Recruiting2024
Pilot phase II study of Selinexor in combination with Ifosfamide Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T cell Lymphomas
2024-513295-18-00 — cells, pilots, dexamethasone, ifosfamide, lymphoma, lymphoma, t-cell, peripheral, etoposide, t-lymphocytes, lymphoma, t-cell
Phase 2Active not recruiting2022
Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B cells non Hodgkin Lymphoma
2023-506206-38-00 — cells, hodgkin disease, lymphoma, rituximab, geriatric assessment, lymphoma, non-hodgkin, therapeutics, b-lymphocytes
Phase 2Recruiting2025

LeadR Networks

Main global connection map